. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Value Health. 2021 Sep 4;25(2):276–287. doi: 10.1016/j.jval.2021.08.002

Table 2.

Health state utilities associated with general sickle cell disease

Author, Year	Study population, Region	Instrument/Method	Health States	Utility Values
*Empirical HSU study*
Ojelabi et al. 2015²⁰	• Adults with SCD • Nigeria	• SF-6D	• SCD in general	• Utility for SCD in general: 0.65 (SD 0.12) • Utility for SCD in general for males: 0.66 (SD 0.11) • Utility for SCD in general for females: 0.64 (SD 0.12) • Utility decrement due to one year older: 0.023 (SE 0.014)
*QALY-based cost-effectiveness analysis*
Bradt et al., 2020²³	• SCD patients • U.S.	• Based on the algorithm reported by Anie et al., which mapped VAS pain score to utility.	• SCD without complication	• Utility for SCD without complication: 0.80
Cherry et al. 2012²⁴	• SCD patients • U.K.	• Based on literature	• SCD with normal TCD velocity	• Utility for SCD with blood velocity of < 200 cm/second: 0.22 (per three months)
*QALY-based simulation modeling study*
Lubeck et al. 2019²⁷	• SCD patients • U.S.	• Based on the algorithm reported by Anie et al., which mapped VAS pain score to utility.	• SCD in general	• Utility for SCD with no pain: 0.887 • Utility for adult with SCD in general: 0.695 • Utility for children or adolescents with SCD in general: 0.692

Abbreviations: HSU = health state utility; NA = not applicable; SCD = sickle cell disease; SD = standard deviation; SF-6D = short form-6D; TCD = Transcranial Doppler; U.K. = United Kingdoms; U.S. = United States; VAS = visual analog scale